MedTrace Logo

New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis

NCT05621343 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2024-06-18

No results posted yet for this study

Summary

Current diagnostic tools such as interferon gamma release assay (IGRA) and purified protein derivative (PPD) can not distinguish patients with latent tuberculosis infection (LTBI) and persistence of live mycobacteria. This inability to rule out living mycobacteria in patients investigated for LTBI leads to unnecessary and potentially harmful treatment regimes all around the globe.

The goal of this observational study is to identify candidate biomarkers for viable bacilli in latent tuberculosis in order to decrease the use of unnecessary and ineffective antibiotic treatment.

Conditions

  • Latent Tuberculosis
  • Persistent Infection
  • Mycobacterium Tuberculosis

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Per Björkman, Professor · Lund University, Faculty of Medicine, Department of Translational Medicine

Eligibility

Min Age
15 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05621343 on ClinicalTrials.gov